U.S. begins targeted vaccine rollout against monkeypox
Jun 29, 2022
HHS is rapidly expanding access to hundreds of thousands of doses of the Jynneos vaccine.
FDA panel supports rollout of tweaked booster shots from Moderna, Pfizer this fall
Jun 29, 2022
The advisory panel approval speeds the process by which FDA regulators will push for updated booster formulations.
COVID-19 vaccines cut mortality with heart failure
Jun 16, 2022
Those who are partially vaccinated and unvaccinated face the same increased risk, whereas boosted and fully vaccinated adults fare best.
One in nine may get delayed large local reaction after Moderna vaccine
Jun 10, 2022
A higher risk was seen among women and among individuals aged 30 to 69 years.
Antibody levels after COVID-19 vaccination inversely linked to body weight
May 23, 2022
An inverse correlation was sustained for up to six months following two doses of BNT162b2 (Pfizer–BioNTech) in a small cohort of healthy young and middle-aged adults.
Adverse effects generally mild after BNT162b2 mRNA booster in over 60s
Apr 18, 2022
Thirty percent of those aged 60 years or older receiving a booster reported at least one adverse event; few sought medical attention.
Risk for myocarditis low after third dose of BNT162b2 vaccine
Mar 24, 2022
The incidence of myocarditis among young men estimated to be 6.43 and 11.25 per 100,000 vaccines in the week to two weeks after third dose..
Neutralization titers against omicron up with mRNA-1273 boost
Jan 28, 2022
After a mRNA-1273 (Moderna) boost, neutralization titers against the omicron variant were 20 times higher than than those at one month after second dose.
Thrombosis, thrombocytopenia syndrome up after Ad26.COV2.S
Jan 28, 2022
Rates of 3.83 per million vaccine doses for Ad26.COV2.S (Johnson & Johnson) have been reported, versus 0.00855 per million for mRNA-based vaccines such as Pfizer-BioNTech and Moderna.
mRNA COVID-19 vaccine less protective in elderly with comorbidity
Dec 23, 2021
At ≥7 days after the second dose, the effectiveness of mRNA COVID-19 vaccine was 69% against infection and 86% against related death.